β-Diketone modified trastuzumab: A next-generation of Herceptin for resistant breast cancer cells?

Medical Hypotheses

Volumn 79, Issue 5, 2012, Pages 602-604

  Lu, Jianguo ^a   Pu, Jun ^a   Lu, Xiaozhao ^a   Fu, Haiyan ^a   Wei, Mengying ^a   Yang, Guodong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIKETONE; INTERLEUKIN 2; RECOMBINANT VACCINE; TRASTUZUMAB;

ACTIVE IMMUNIZATION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CELL DEATH; CELL GROWTH; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNITY; MEMORY; PASSIVE IMMUNIZATION; PATIENT;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; KETONES;

EID: 84867330817     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.07.030     Document Type: Article

References (17)

1. Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24:2137-2150.
2. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics. CA Cancer J Clin 2006, 56(2006):106-130.
3. Yarden Y. Family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001, 37(Suppl. 4):S3-8.
4. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-137.
5. Cho H.S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney D.W., et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003, 421:756-760.
6. Brennan P.J., Kumagai T., Berezov A., Murali R., Greene M.I. HER2/neu: mechanisms of dimerization/oligomerization. Oncogene 2000, 19:6093-6101.
7. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
8. Hudis C.A. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 2007, 357:39-51.
9. Valabrega G., Montemurro F., Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007, 18:977-984.
10. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000, 6:443-446.
11. Nimmerjahn F., Ravetch J.V. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008, 8:34-47.
12. Repka T., Chiorean E.G., Gay J., Herwig K.E., Kohl V.K., Yee D., et al. Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. Clin Cancer Res 2003, 9:2440-2446.
13. Popkov M., Gonzalez B., Sinha S.C., Barbas C.F. Instant immunity through chemically programmable vaccination and covalent self-assembly. Proc Natl Acad Sci USA 2009, 106:4378-4383.
14. Wagner J., Lerner R.A., Barbas C.F. Efficient aldolase catalytic antibodies that use the enamine mechanism of natural enzymes. Science 1995, 270:1797-1800.
15. Frasca D., Landin A.M., Riley R.L., Blomberg B.B. Mechanisms for decreased function of B cells in aged mice and humans. J Immunol 2008, 180:2741-2746.
16. Song H., Price P.W., Cerny J. Age-related changes in antibody repertoire: contribution from T cells. Immunol Rev 1997, 160:55-62.
17. Swarts J.C., Vosloo T.G., Cronje S.J., Du Plessis W.C., Van Rensburg C.E., Kreft E., et al. Cytotoxicity of a series of ferrocene-containing beta-diketones. Anticancer Res 2008, 28:2781-2784.